Krystal Biotech, Inc. (NASDAQ:KRYS) to Post Q3 2024 Earnings of $0.89 Per Share, William Blair Forecasts

Krystal Biotech, Inc. (NASDAQ:KRYS) – Equities researchers at William Blair upped their Q3 2024 EPS estimates for shares of Krystal Biotech in a note issued to investors on Monday, August 5th. William Blair analyst T. Lugo now expects that the company will post earnings per share of $0.89 for the quarter, up from their prior forecast of $0.63. The consensus estimate for Krystal Biotech’s current full-year earnings is $2.00 per share. William Blair also issued estimates for Krystal Biotech’s Q4 2024 earnings at $0.97 EPS and FY2024 earnings at $2.75 EPS.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, August 5th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.50 by $0.03. The company had revenue of $70.28 million during the quarter, compared to analyst estimates of $65.27 million. Krystal Biotech’s revenue for the quarter was up 70283900.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.25) EPS.

Several other equities research analysts have also recently issued reports on KRYS. Chardan Capital raised their price objective on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research report on Monday, August 5th. Citigroup reissued a “neutral” rating and issued a $204.00 price target (up from $195.00) on shares of Krystal Biotech in a research note on Tuesday. Stifel Nicolaus reiterated a “buy” rating and issued a $204.00 target price (up previously from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. Finally, HC Wainwright restated a “buy” rating and set a $200.00 price target on shares of Krystal Biotech in a research report on Monday, August 5th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $185.63.

Krystal Biotech Stock Up 1.0 %

Shares of KRYS traded up $1.80 during midday trading on Thursday, reaching $182.17. The company had a trading volume of 144,558 shares, compared to its average volume of 379,286. Krystal Biotech has a 1-year low of $93.95 and a 1-year high of $219.34. The firm has a 50 day simple moving average of $186.63 and a 200-day simple moving average of $164.72. The stock has a market cap of $5.20 billion, a PE ratio of 97.42 and a beta of 0.84.

Insider Buying and Selling at Krystal Biotech

In other news, Director Julian S. Gangolli sold 20,000 shares of Krystal Biotech stock in a transaction on Monday, May 20th. The shares were sold at an average price of $164.13, for a total transaction of $3,282,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the completion of the sale, the insider now owns 1,525,882 shares in the company, valued at $268,189,020.32. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Julian S. Gangolli sold 20,000 shares of the stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $164.13, for a total transaction of $3,282,600.00. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

Several hedge funds and other institutional investors have recently bought and sold shares of KRYS. Jamison Private Wealth Management Inc. acquired a new stake in shares of Krystal Biotech in the second quarter valued at approximately $28,000. GAMMA Investing LLC increased its position in Krystal Biotech by 160.3% during the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after buying an additional 93 shares in the last quarter. Key Financial Inc acquired a new position in shares of Krystal Biotech in the second quarter worth $28,000. Blue Trust Inc. lifted its position in shares of Krystal Biotech by 2,328.6% in the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after acquiring an additional 163 shares in the last quarter. Finally, Quest Partners LLC purchased a new stake in Krystal Biotech during the 2nd quarter worth about $71,000. 86.29% of the stock is owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).